07:00 , Jul 18, 2011 |  BioCentury  |  Strategy

mAbs are icing on the cake

Biotest AG has returned to its roots in plasma proteins. After selling off its tools and diagnostics businesses, the company is looking to grow by increasing its plasma protein product offerings and expanding its global...
08:00 , Nov 22, 2010 |  BioCentury  |  Regulation

Mild Was Enough

Leading up to last week's advisory committee meeting to discuss a BLA for lupus candidate Benlysta belimumab from Human Genome Sciences Inc., the outcome hardly looked like a slam dunk. Based on a pair of...
03:21 , Nov 2, 2005 |  BC Extra  |  Financial News

Biotest raises $38.1 million

Biotest (FSE:BIO) raised EUR 31.6 million ($38.1 million) in a rights offering of 857,000 ordinary shares at EUR 22.50 and 667,000 preferred shares at EUR 18.50. The underwriters are Commerzbank; Landes Baden-Wuerttemberg; and equinet Securities....
00:17 , Oct 12, 2005 |  BC Extra  |  Financial News

Biotest to raise EUR 31.6 million

Biotest (FSE:BIO) proposed to raise EUR 31.6 million ($38.3 million) in a rights offering. The company plans to sell 857,000 ordinary shares at EUR 22.50 and 667,000 preference shares at EUR 18.50. The non-voting preference...